Global Ribonucleic Acid (RNA) Therapy Clinical Trials Market Size, Share, and Forecast Analysis 2025-2029

Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.

What Are the Ribonucleic Acid (RNA) Therapy Clinical Trials Market Size Forecast for 2025?
In recent times, there has been a significant increase in the size of the ribonucleic acid (RNA) therapy clinical trials market. The market is projected to expand from $2.57 billion in 2024 to $2.70 billion in 2025, experiencing a compound annual growth rate (CAGR) of 5.0%. Several factors have contributed to this growth in the historic period, including an increased demand for innovative therapies, the rising success rates of mRNA vaccines, growth in research funding, a surge in clinical trial activities, and a growing need for comparative genomics.

What Is the Market Size Outlook for Ribonucleic Acid (RNA) Therapy Clinical Trials Until 2029?
The market size for clinical trials on ribonucleic acid (RNA) therapy is predicted to experience consistent expansion in the coming years, reaching $3.25 billion by 2029 with a compound annual growth rate (CAGR) of 4.8%. Several factors are contributing to this growth in the projected period, such as the growing occurrence of rare diseases, an increase in regulatory approvals, a boosted investment in clinical study, a rise in patient engagement, and a heightened concentration on personalized medicine. Key trends for the forecasted period involve improvements in RNA delivery systems, progress in biomarker-focused trial systems, the incorporation of artificial intelligence in trial planning, the use of technology in decentralized clinical trials, and enhancements in regulatory fast-track processes.

Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/ribonucleic-acid-rna-therapy-clinical-trials-global-market-report

What Are the Major Factors Driving Demand in the Ribonucleic Acid (RNA) Therapy Clinical Trials Market?
The escalation of infectious diseases is predicted to stimulate the expansion of the ribonucleic acid (RNA) therapy clinical trials market. Infectious diseases, which are health conditions triggered by harmful microorganisms like bacteria, viruses, fungi, or parasites, proliferate within the human body, causing health deterioration. The surge in these diseases is primarily due to increasing global travel, which aids quick transmission of pathogens across different regions and population groups. Ribonucleic acid (RNA) therapy clinical trials play a crucial role in dealing with infectious diseases as they facilitate the progress and assessment of specialized treatments that can promptly adjust to new pathogens. For instance, a report released in April 2025 by the Minnesota Department of Health, a US-based state institution, revealed significant growth in HIV cases among males aged 35 to 39, rising from 10% in 2023 to 17% in 2024. Thus, the growing burden of infectious diseases is fuelling the expansion of the ribonucleic acid (RNA) therapy clinical trials market.

Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25896&type=smp

How Are End-Use Segments Shaping the Ribonucleic Acid (RNA) Therapy Clinical Trials Market Outlook?
The ribonucleic acid (rna) therapy clinical trials market covered in this report is segmented -

1) By Modality: Ribonucleic Acid (RNA) Interference, Antisense Therapy, Messenger Ribonucleic Acid (RNA), Oligonucleotide, Non-Antisense, Non-Ribonucleic Acid Interference (RNAi)
2) By Clinical Trials Phase: Phase I, Phase II, Phase III, Phase IV
3) By Therapeutic Areas: Rare Diseases, Anti-Infective, Anticancer, Neurological, Alimentary Or Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas

Subsegments:

1) By Ribonucleic Acid (RNA) Interference: Small Interfering RNA (siRNA) Therapy Trials, MicroRNA (miRNA)-Based Therapy Trials, Short Hairpin RNA (shRNA) Therapy Trials, Dicer Substrate RNA Therapy Trials
2) By Antisense Therapy: Gapmer Antisense Oligonucleotide Trials, Steric Blocking Antisense Trials, Splice-Switching Antisense Oligonucleotide Trials, Antisense Oligonucleotide-Conjugated Delivery Trials
3) By Messenger Ribonucleic Acid (RNA): mRNA-Based Vaccines Trials, Self-Amplifying mRNA (saRNA) Therapy Trials, Non-Replicating mRNA Therapy Trials, Circular mRNA Therapy Trials
4) By Oligonucleotide: Phosphorothioate Oligonucleotide Trials, Peptide Nucleic Acid (PNA) Trials, Locked Nucleic Acid (LNA) Trials, Morpholino Oligonucleotide Trials
5) By Non-Antisense: RNA Aptamer Therapy Trials, Guide RNA (gRNA)-Mediated CRISPR Trials, RNA Editing Therapy Trials, RNA Scaffolding Or Regulatory RNA Therapy Trials
6) By Non-Ribonucleic Acid Interference (RNAi): Ribozymes Therapy Trials, RNA Decoys Or Sponge RNA Trials, Long Non-Coding RNA (lncRNA) Therapy Trials, Small Activating RNA (saRNA) Therapy Trials

What Are the Strategic Trends Transforming the Ribonucleic Acid (RNA) Therapy Clinical Trials Market Landscape?
In the ribonucleic acid (RNA) therapy clinical trials market, large companies are concentrating their efforts on creating new solutions like RNA-based antisense oligonucleotide therapy clinical trials. These aim to target specific genetic sequences, regulate gene expression and provide highly accurate treatments for genetic and rare diseases. An RNA-based antisense oligonucleotide therapy clinical trial examines the use of abbreviated synthetic RNA strands that bind to specific messenger RNA targets to control gene expression and handle genetic abnormalities. Sepul Bio, a biotech firm based in France, for instance, launched the LUNA Phase 2b clinical trial in December 2024 to investigate ultevursen, an RNA-based antisense oligonucleotide therapy that zeroes in on mutations in exon 13 of the USH2A gene, a cause of retinitis pigmentosa (RP) and Usher syndrome type 2a. This is a two-year, double-masked, randomized, and sham-controlled study that will recruit 81 adults and children eight years and older from around the world. This therapy is aimed at people with RP or non-syndromic RP due to mutations in exon 13 of USH2A, which can be validated through genetic testing. The LUNA trial follows promising outcomes from earlier Phase 1/2 studies, in which ultevursen demonstrated improvements in vision clarity, retinal sensitivity, and retinal structure.

Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25896&type=smp

Who Are the Prominent Companies in the Ribonucleic Acid (RNA) Therapy Clinical Trials Market by ?
Major companies operating in the ribonucleic acid (rna) therapy clinical trials market are Pfizer Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Moderna Inc., BioNTech SE, Biogen Inc., Daiichi Sankyo Company Limited, Charles River Laboratories International Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Cartesian Therapeutics Inc., CureVac N.V., Orna Therapeutics Inc., Silence Therapeutics plc, ETHRIS GmbH, ProQR Therapeutics N.V., Lexeo Therapeutics Inc., Avidity Biosciences Inc., Aro Biotherapeutics Company, Wave Life Sciences Ltd.

Which Region Is Expected to See the Highest CAGR in the Ribonucleic Acid (RNA) Therapy Clinical Trials Market?
North America was the largest region in the ribonucleic acid (RNA) therapy clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ribonucleic acid (rna) therapy clinical trials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.